IGI reports phase 1 results of ISB 2001 trispecific antibody in relapsed or refractory multiple myeloma Read more
Ichnos Glenmark Innovation to present phase 1 study data on Trispecific Antibody ISB 2001 at ASH Annual Meeting Read more
Glenmark and Ichnos launch Ichnos Glenmark Innovation to accelerate new drug discovery in cancer treatment Read more